Humacyte's Symvess approval signals growth in regenerative medicine. See why HUMA stock is not yet a buy as we monitor its ...

Graham Corporation stock delivering exceptional returns, backed by strong backlog growth and earnings. Learn more about GHM ...

NVDA CEO Huang estimates 20 years before useful quantum computers. AMC CEO feels shareholder pain. Sportsbooks hit as too ...

Wells Fargo's strong fundamentals provide resilience against volatility. Find out why WFC stock remains fairly valued with ...

Advanced Micro Devices lags Nvidia in AI design wins, prompting a downgrade to sell. See why AMD stock faces little room to ...

Lazard Global Total Return and Income Fund offers 10.98% yield, trading at a discount. Read why LGI CEF presents long-term ...

Tesla's AI business drives 70% of its valuation, raising concerns. See why TSLA stock is overvalued and carries significant ...

The portfolio’s primary goal is to have a high dividend yield, and on that front, it’s firing on all cylinders, with a ...

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Innodata's strong partnerships, AI focus, and growth potential make it an attractive buy with a $65 price target by early ...

ASML Holding dominates EUV lithography, key for AI and 5G. See why ASML stock remains a strong buy for long-term investors ...

Stryker's acquisition of Inari for $4.9B enhances its neurovascular portfolio and boosts revenue growth by 50bp, with minimal ...